Alberici P, Jagmohan-Changur S, De Pater E, Van Der Valk M, Smits R, Hohenstein P, Fodde R
Department of Pathology, Josephine Nefkens Institute, ErasmusMC, Rotterdam, The Netherlands.
Oncogene. 2006 Mar 23;25(13):1841-51. doi: 10.1038/sj.onc.1209226.
The Smad4(+/E6sad) mouse carries a null mutation in the endogenous Smad4 gene resulting in serrated adenomas and mixed polyposis of the upper gastrointestinal (GI) tract with 100% penetrance. Here, we show by loss of heterozygosity (LOH) analysis and immunohistochemistry (IHC) that, although the majority of the tumors appear at 9 months of age, somatic loss of the wild-type Smad4 allele occurs only at later stages of tumor progression. Hence, haploinsufficiency underlies Smad4-driven tumor initiation in the GI tract. As both the Apc and Smad4 tumor suppressor genes map to mouse chromosome 18, we have bred Smad4(+/E6sad) with the Apc(+/1638N) model to generate two distinct compound heterozygous lines carrying both mutations either in cis (CAS) or in trans (TAS). Strikingly, both models show increased tumor multiplicities when compared with the single mutant littermates, although CAS mice are more severely affected and became moribund at only 5-6 weeks of age. Phenotypic and molecular analyses indicate that Smad4 haploinsufficiency is sufficient to significantly affect tumor initiation and progression both prior to and upon loss of Apc function. Moreover, complete loss of Smad4 strongly enhances Apc-driven tumor formation.
Smad4(+/E6sad)小鼠的内源性Smad4基因存在无效突变,导致上消化道(GI)出现锯齿状腺瘤和混合性息肉,且发病率为100%。在此,我们通过杂合性缺失(LOH)分析和免疫组织化学(IHC)表明,尽管大多数肿瘤在9个月大时出现,但野生型Smad4等位基因的体细胞缺失仅发生在肿瘤进展的后期阶段。因此,单倍体不足是Smad4驱动的胃肠道肿瘤起始的基础。由于Apc和Smad4肿瘤抑制基因都定位于小鼠18号染色体,我们将Smad4(+/E6sad)与Apc(+/1638N)模型杂交,以产生两个不同的复合杂合子品系,它们的两个突变要么是顺式(CAS)要么是反式(TAS)。令人惊讶的是,与单突变同窝小鼠相比,这两个模型的肿瘤数量都增加了,尽管CAS小鼠受影响更严重,仅在5 - 6周龄时就濒死。表型和分子分析表明,Smad4单倍体不足足以在Apc功能丧失之前和之后显著影响肿瘤的起始和进展。此外,Smad4的完全缺失强烈增强了Apc驱动的肿瘤形成。